Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19
On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…
CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics
On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…
Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine against SARS-CoV-2
On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…
Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 study
On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…
Biotechnology | COVID-19 | FDA
OraSure’s DNA Genotek subsidiary received FDA EUA for its ORAcollect-RNA saliva collectiondevice for SARS CoV-2
On Nov. 3, 2020, OraSure Technologies announced its DNA Genotek subsidiary has received Emergency Use Authorization from the…
Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
UK MHRA began rolling review of Moderna’s mRNA COVID-19 vaccine
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Moderna announced supply agreement with Qatar for mRNA vaccine against COVID-19
On Oct. 26, 2020, Moderna announced a supply agreement with the Ministry of Public Health of Qatar for…
Todos Medical announced instrument validation completed at MOTO+PARA Mobile Lab
On Oct. 26, 2020, Todos Medical announced the completion of the instrument validation in its mobile lab division….
Roche announced collaboration with Atea Pharmaceuticals to develop potential oral treatment for COVID-19 patients
On Oct. 22, 2020, Roche and Atea Pharmaceuticals announced they had joined forces in the fight against COVID-19…
Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
RNA ‘ticker tape’ records gene activity over time
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…
Pfizer and BioNTech announced publication of phase 1 data on lead mRNA vaccine candidate against COVID-19
On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of…
Moderna announced initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
Rentschler Biopharma contributed to manufacturing of COVID-19 mRNA vaccine
On Oct. 7, 2020, Rentschler Biopharma announced an agreement to serve as CDMO partner for BioNTech. As an…
LabCorp COVID-19 molecular test innovation received FDA authorization
On Oct. 2, 2020, LabCorp announced that it had received an Emergency Use Authorization (EUA) from the FDA…
BioNTech and Pfizer announced Nature publication of German phase 1/2 study data from mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 30, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2…
Investigational COVID-19 vaccine well tolerated and generated iImmune response in older adults
On Sept. 29, 2020, the National Institute of Allergy and Infectious Diseases announced that a phase 1 trial…
Moderna announced publication in The NEJM of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Sept. 29, 2020, Moderna announced the publication of the second interim analysis of the open-label Phase 1…
Biotechnology | NIH | Vaccine
COVID-19 vaccine generated immune response in older adults
On Sept. 29, 2020, a phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection was…
Evaluation of LamPORE rapid tests for Covid-19 showed high levels of diagnostic sensitivity
On Sept. 25, 2020, scientists from the University of Oxfordﾒs Nuffield Department of Medicine published their evaluation of…
Pfizer and BioNTech announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
Pfizer and BioNTech to potentially supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 9, 2020, Pfizer and BioNTech announced that they had submitted an amended protocol to the FDA…
BioNTech and Pfizer announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
Biotechnology | COVID-19 | FDA
OraSure’s ORAcollect-RNA device Included in EUA granted to MiraDx for SARS-CoV-2 test
On Sept. 3, 2020, OraSure Technologies announced that its ORAcollect-ﾷRNA (OR-100) collection device was included along with other…
Ceres received $65M NIH award to expand Nanotrapﾮ particle manufacturing capacity for COVID-19 testing
On Sept. 2, 2020, Ceres Nanosciences announced it had been awarded a contract from the National Institutes of…
Disease | NIH | Therapeutics
NIAID awarded BioCryst $44 million contract to advance development of galidesivir
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…